First in Man Study of the DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-II)
A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 123 participants.
Also called NCT01960504
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 123 participants
- Sponsor
- Registry
-
NCT01960504
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- Belgium, Brazil, Denmark, Germany, Netherlands, Singapore, Spain, Switzerland
- Registry status
- Unknown status
Technical summary
Registry record NCT01960504. Allocation not applicable; no masking; primary purpose treatment. Start 2013-10 (actual); primary completion 2015-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- First in Man Study of the DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-II)
- Acronym
- BIOSOLVE-II
- Condition
- Coronary Artery Disease
- Condition
- Coronary Artery Stenosis
- Intervention (Device)
- Percutaneous Coronary Intervention (DREAMS) stenting
- Lead sponsor
- Biotronik AG
Record details
- Record id
cardio:ct-nct01960504- Content hash
8203ae27c986d5461b46a455e7c079f1f0a2e425ea706a2e25f3862e76a94328